Gain Therapeutics (GANX)
(Delayed Data from NSDQ)
$1.12 USD
-0.08 (-6.67%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $1.12 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Brokerage Reports
Gain Therapeutics, Inc. [GANX]
Reports for Purchase
Showing records 1 - 20 ( 21 total )
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
GT-02287 Abstract Accepted at European Conference; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Key Legislation Passes Congress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
1Q24 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
GT-02287 Generates Positive Early Clinical Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
GT-02287 Continues to Show Promise; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
GT-02287 Preclinical Efficacy Profile Remains Intriguing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Clinical Progress Continues; Equity Financing; Lowering PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Clinical Milestones Approaching; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
GT-02287 Phase 1 Trial Dosing Initiation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
GT-02287 Phase 1 Healthy Volunteers Trial Near-Term Start; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
GT-02287 Potential Highlighted in Poster Presentations; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Transition Into Clinical Development; 2Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
1Q23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Parkinson''s Disease Prioritization; New Finance Chief Appointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Leadership Transition; 3Q22 Financials; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
New Animal Model Data Strengthen Parkinson?s Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Multiple Preclinical Datasets Presented; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Positive Preclinical Data Presented on Parkinson''s Candidate; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
New Preclinical Data Showcases Gaucher Program Strength; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Gain Therapeutics, Inc.
Industry: Medical - Drugs
Hitting Novel Allosteric Sites to Design New Drugs; Initiate at Buy; $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R